

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Baijin Life Science Holdings Limited

佰金生命科學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1466)

**(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
(2) NON-COMPLIANCE WITH THE LISTING RULES;
AND
(3) CHANGES TO AUDIT COMMITTEE MEMBERSHIP**

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Baijin Life Science Holdings Limited (the “**Company**”) announces that Mr. Lee Ka Leung Daniel (“**Mr. Lee**”) has resigned as an independent non-executive Director and ceased to be the chairman of the audit committee (the “**Audit Committee**”) and a member of each of the remuneration committee (the “**Remuneration Committee**”) and the nomination committee (the “**Nomination Committee**”) of the Company with effect from 27 January 2026 due to his personal reasons.

Mr. Lee has confirmed that he has no disagreement with the Board and the Company and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude and appreciation to Mr. Lee for his valuable contributions to the Company during his term of office.

NON-COMPLIANCE WITH THE LISTING RULES

Rules 3.10(1) and 3.10A of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) provide that the board of directors of a listed issuer must include at least three INEDs and these INEDs must represent at least one-third of the board. Rule 3.21 of the Listing Rules provides that the Audit Committee shall comprise at least three members. Rule 3.25 of the Listing Rules provides that the Remuneration Committee shall maintain a majority of independent non-executive Directors. Rule 3.27A of the Listing Rules provides that the Nomination Committee shall maintain a majority of independent non-executive Directors. Following the resignation of Mr. Lee, the Company has failed to comply with the requirements as set out in Rules 3.10(1), 3.10A, 3.21, 3.25 and 3.27A of the Listing Rules. In order to ensure compliance with the Listing Rules, the Company will make

its best endeavour to identify a suitable candidate to fill the casual vacancy of the Board and appoint appropriate person to the Audit Committee, the Remuneration Committee and Nomination Committee. Further announcement(s) will be made in this regard as and when appropriate in accordance with the requirements of the Listing Rules.

CHANGES TO AUDIT COMMITTEE MEMBERSHIP

Following the resignation of Mr. Lee, the Board announces that with effect from 27 January 2026, Mr. Wong Siu Keung Joe, an independent non-executive Director, has been appointed as the chairman of the Audit Committee.

By order of the Board
BAIJIN LIFE SCIENCE HOLDINGS LIMITED
Cheung Sze Ming
Executive Director

Hong Kong, 27 January 2026

As at the date of this announcement, the Board comprises Mr. Cheung Sze Ming, Mr. Dong Peng and Dr. Su Yaoyao as executive Directors; Mr. Zhu Yongjun, Mr. Cheng Chi Kin and Ms. Xie Chunchen as non-executive Directors; Mr. Wong Siu Keung Joe and Mr. Chang Chunyu as independent non-executive Directors.